The BRAFi therapy-induced senescence (TIS) in the cancer cells, and the development of secondary cSCCs with BRAF inhibitor treatment relies on upregulation of the MAPK pathway or alternative pathways in keratinocytes that often have senescence driving alterations such has RAS oncogene activation or HPV infection. This evidence concerns the gene BRAF and cancer.